Mirum Pharmaceuticals came into this earnings season with a bruised stock, down over 26% in the past month, and the selloff accelerated today with an 11% slide to about US$94. Yet the headline from Q2 is not collapse but commercial heft. Net product sales reached US$176.2m and management lifted full year 2026 sales guidance to a range of US$680m to US$700m. The catch sits on the income statement. Mirum reported a quarterly net loss of US$67.2m and basic earnings per share of US$1.06 in the red, keeping the profit debate wide open.

Love Mirum Pharmaceuticals’ growing product sales but concerned about the ongoing net losses? Take a look at 78 resilient stocks with low risk scores.

Q2 2026 Earnings Summary

• Total Revenue (Q2 2026 vs. Q2 2025): US$176.2m vs. US$127.8m (higher year over year)
• Net Income or Loss (Q2 2026 vs. Q2 2025): loss of US$67.2m vs. loss of US$5.9m (loss widened)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$1.06 per share vs. loss of US$0.12 per share (per share loss widened)
• Commercial Cash Contribution Margin (Q2 2026 vs. Q2 2025): high 50s % vs. high 40s % (improved by about 5 percentage points)

If you prefer clean, interactive charts instead of a dense wall of earnings tables and footnotes, you can see Mirum Pharmaceuticals’ full financial picture, including a clear view of its profitability path and recent losses, in our company report for Mirum Pharmaceuticals.

Mirum bull case leans on commercial and pipeline proof

The upbeat narrative around Mirum Pharmaceuticals says a growing rare disease franchise and a richer pipeline can support a higher, more durable earnings base. Q2 gives this view some support. Net product sales of US$176.2m and higher 2026 guidance to US$680m to US$700m show Mirum is finding and treating more patients, helped by genetic testing in PFIC and broader LIVMARLI use. A commercial cash contribution margin in the high 50s % also points to improving unit economics. On the pipeline side, Breakthrough Therapy status for volixibat in PSC and a September 2026 PDUFA date for zilurgisertib in FOP keep the multi asset growth story alive. The stronger cash balance of US$561m and the low coupon converts extend funding for launches and trials.

Bear case focuses on losses, delays and concentration risk

The cautious view says Mirum is over dependent on a narrow portfolio, carries heavy R&D and faces real regulatory and financing risk. Q2 gives that argument fresh support. Net loss widened to US$67.2m even as revenue grew, and basic EPS loss deepened to US$1.06. Total operating expenses of US$219m, including US$76m of R&D and US$16m of in process R&D for zilurgisertib, show the cost of sustaining the pipeline. Volixibat’s PSC filing is now pushed to the first half of 2027 after the FDA asked for a Phase 3, which delays that revenue stream. The stock is also reacting. The share price fell about 11% today and has declined over 26% in the past month, suggesting investors are repricing execution and concentration risks despite raised sales guidance.

After a quarter where Mirum Pharmaceuticals reported wider losses despite higher revenue and past shareholder dilution, it is worth asking whether these are early signs of deeper structural issues. Review our independent risk analysis for Mirum Pharmaceuticals which shows 2 important warning signs

Stay Ahead With Mirum Pharmaceuticals Insights

With Mirum Pharmaceuticals showing strong product sales alongside ongoing losses, it can help to keep the stock on your radar rather than rush a decision. Register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and watch how the story around losses and guidance develops. If you already hold Mirum Pharmaceuticals, use the Portfolio Command Center to cut through the noise and receive focused updates on earnings, balance sheet changes and key regulatory milestones. Then round out your view with crowd insights through the Community so you can spot potential catalysts or emerging risks early and stay ahead of the market.

Seeking Alternatives Beyond Mirum Pharmaceuticals

Fresh stock ideas can start to move before the crowd even notices. Spot breakout stories while momentum is building and information is still under the radar for now. Act now.

• Scan for potential breakout stability by reviewing companies in the 78 resilient stocks with low risk scores before they get fully caught by the wider market and pricing gets less forgiving.
• Tap into early momentum in companies with strong cash generation and balance sheets by checking the curated list of solid balance sheet and fundamentals stocks (49 results) while they are still flying under the radar.
• Explore fresh income ideas that aim to keep yields steady by reviewing the hand picked 9 dividend fortresses before the best entry points start dropping away.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.